2024
DOI: 10.1177/10892532241249582
|View full text |Cite
|
Sign up to set email alerts
|

Year in Review 2023: Noteworthy Literature in Cardiothoracic Critical Care

Sarah Alber,
Kenji Tanabe,
Andrew Hennigan
et al.

Abstract: This article reviews noteworthy investigations and society recommendations published in 2023 relevant to the care of critically ill cardiothoracic surgical patients. We reviewed 3,214 articles to identify 18 publications that add to the existing literature across a variety of topics including resuscitation, nutrition, antibiotic management, extracorporeal membrane oxygenation (ECMO), neurologic care following cardiac arrest, coagulopathy and transfusion, steroids in pulmonary infections, and updated guidelines… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 64 publications
0
1
0
Order By: Relevance
“…In this issue’s first review, Alber et al elaborated on exciting updates in the field of critical care. 4 The authors discussed how the European Society of Intensive Care Medicine and American Thoracic Society updated management guidelines for ARDS with many important lessons learned from the COVID-19 pandemic. 5,6 In two potentially practice-changing randomized controlled trials (RCTs) included in this review, hydrocortisone improved 28-day mortality in severe community-acquired pneumonia, 7 and preventive inhaled amikacin decreased the rate of ventilator-associated pneumonia at 28 days.…”
Section: Critical Carementioning
confidence: 99%
“…In this issue’s first review, Alber et al elaborated on exciting updates in the field of critical care. 4 The authors discussed how the European Society of Intensive Care Medicine and American Thoracic Society updated management guidelines for ARDS with many important lessons learned from the COVID-19 pandemic. 5,6 In two potentially practice-changing randomized controlled trials (RCTs) included in this review, hydrocortisone improved 28-day mortality in severe community-acquired pneumonia, 7 and preventive inhaled amikacin decreased the rate of ventilator-associated pneumonia at 28 days.…”
Section: Critical Carementioning
confidence: 99%